COURT-RULING ·Filed Aug 11, 2026

ABT

ABBOTT LABORATORIES
NEUTRAL
Impact 1/10
Horizonimmediate Processed1mo ago CourtView Ruling on CourtListener
Court ruling (district)
Actionable Insight • Neutral

No trading action warranted. This is a routine scheduling extension with zero material impact on Abbott's financials, operations, or litigation risk profile. Monitor for future substantive rulings on class certification or summary judgment.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
ABT ▼ -4.09% at T+20d
NEUTRAL call ✗ call lost -4.09% · α vs SPY -3.03% · entry $109.72 → $105.23
Next anchor: T+60d in 5w
Latest observation: T+35 -21.52% FF3 residual α
Entry anchored
Aug 10, 04:47 PM ET
via 1-min bar
T+1d
+1.08%
call +1.08% · α +0.83%
$110.91
settled 7w ago
T+5d
+2.70%
call +2.70% · α +3.10%
$112.68
settled 7w ago
T+20d
-4.09%
call -4.09% · α -3.03%
$105.23
settled 24d ago
T+60d
—
call — · α —
—
in 5w

Price Chart

Loading chart...

Executive Summary

This is a routine procedural stipulation in the multi-district FreeStyle CGM consumer litigation against Abbott Diabetes Care Inc. and Abbott Laboratories. The parties jointly requested, and the court granted, a one-month extension of the deadline to submit a proposed ESI protocol from August 12 to September 14, 2026. This is the third such extension and has no bearing on the merits, liability, or financial exposure of the case.

Court Ruling Details

Ruling Date
Aug 11, 2026
Court
United States District Court for the Northern District of California
Court Level
District
Judge
Haywood S. Gilliam, Jr.
Case Type
other
Ruling Type
procedural
Outcome
SETTLEMENT — parties reached agreement
Will It Be Appealed?
N/A (final)
Precedent Risk
LOW

Key Facts

  • Parties jointly stipulated to extend the ESI protocol deadline to September 14, 2026.
  • This is the third stipulated extension in the case (ECF Nos. 39, 57, 68).
  • The order does not alter any other case deadlines or substantive rulings.
  • The underlying litigation is a consumer class action over FreeStyle CGM products.

Financial Impact

No financial impact — purely procedural scheduling order with no damages, liability determination, or injunction.

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Price
$110.94
Volume
200
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
73% bullish (33 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 court opinion from CourtListener.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-1d630f42bf-ABT
22 reports for ABT
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+20▲ +17.16%Jul 1, 2026
Filters
Rows
Reports for ABT — sortable, filterable
TypeNow
Oct 2, 2026
today
ANALYST-UPGRADE
BULLISH ★ 4/10
$98.00 awaiting T+5awaiting T+5—$96.69 (−1.34%)
Sep 14, 2026
18d ago
Court Ruling
NEUTRAL ★ 1/10
$103.09 $102.98▼ −0.11%▼ −1.77%$96.69 (−6.21%)
Aug 11, 2026
7w ago
Court Ruling
NEUTRAL ★ 2/10
$109.72 $112.68▲ +2.70%▲ +3.10%$96.69 (−11.88%)
Aug 11, 2026
7w ago
Court Ruling
NEUTRAL ★ 1/10
$109.72 $112.68▲ +2.70%▲ +3.10%$96.69 (−11.88%)
Jul 31, 2026
9w ago
Institutional Cluster
MIXED ★ 4/10
$105.70 $107.81▲ +2.00%▼ −1.51%$96.69 (−8.52%)
Jul 31, 2026
9w ago
Court Ruling
NEUTRAL ★ 2/10
$105.70 $107.81▲ +2.00%▼ −1.51%$96.69 (−8.52%)
Jul 24, 2026
10w ago
Court Ruling
BULLISH ★ 5/10
$103.06 $105.61▲ +2.47%▲ +2.10%$96.69 (−6.18%)
Jul 16, 2026
11w ago
8-K
BULLISH ★ 6/10
$98.83 $100.75▲ +1.94%▲ +3.61%$96.69 (−2.17%)
Jul 14, 2026
11w ago
Court Ruling
NEUTRAL ★ 3/10
$88.96 $101.66▲ +14.28%▲ +15.57%$96.69 (+8.69%)
Jul 7, 2026
12w ago
Court Ruling
NEUTRAL ★ 1/10
$95.84 $88.96▼ −7.18%▼ −7.73%$96.69 (+0.89%)
Showing 10 of 22

US Market Status

Market Open — Closes in 6h 29m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access